Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

    Research output: Contribution to journalLetterpeer-review

  2. Lower or Higher Oxygenation Targets for Acute Hypoxemic Respiratory Failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Monoclonal Antibody for Patients with Covid-19. Reply

    Research output: Contribution to journalLetterpeer-review

  5. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effects of endogenous GIP in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND Weight regain after weight loss is a major problem in the treatment of persons with obesity. METHODS In a randomized, head-to-head, placebo-controlled trial, we enrolled adults with obesity (body-mass index [the weight in kilograms divided by the square of the height in meters], 32 to 43) who did not have diabetes. After an 8-week low-calorie diet, participants were randomly assigned for 1 year to one of four strategies: a moderate-to-vigorous–intensity exercise program plus placebo (exercise group); treatment with liraglutide (3.0 mg per day) plus usual activity (liraglutide group); exercise program plus liraglutide therapy (combination group); or placebo plus usual activity (placebo group). End points with prespecified hypotheses were the change in body weight (primary end point) and the change in body-fat percentage (secondary end point) from randomization to the end of the treatment period in the intention-to-treat population. Prespecified metabolic health-related end points and safety were also assessed. RESULTS After the 8-week low-calorie diet, 195 participants had a mean decrease in body weight of 13.1 kg. At 1 year, all the active-treatment strategies led to greater weight loss than placebo: difference in the exercise group, −4.1 kg (95% confidence interval [CI], −7.8 to −0.4; P=0.03); in the liraglutide group, −6.8 kg (95% CI, −10.4 to −3.1; P<0.001); and in the combination group, −9.5 kg (95% CI, −13.1 to −5.9; P<0.001). The combination strategy led to greater weight loss than exercise (difference, −5.4 kg; 95% CI, −9.0 to −1.7; P=0.004) but not liraglutide (−2.7 kg; 95% CI, −6.3 to 0.8; P=0.13). The combination strategy decreased body-fat percentage by 3.9 percentage points, which was approximately twice the decrease in the exercise group (−1.7 percentage points; 95% CI, −3.2 to −0.2; P=0.02) and the liraglutide group (−1.9 percentage points; 95% CI, −3.3 to −0.5; P=0.009). Only the combination strategy was associated with improvements in the glycated hemoglobin level, insulin sensitivity, and cardiorespiratory fitness. Increased heart rate and cholelithiasis were observed more often in the liraglutide group than in the combination group. CONCLUSIONS A strategy combining exercise and liraglutide therapy improved healthy weight loss maintenance more than either treatment alone.

Original languageEnglish
JournalThe New England journal of medicine
Volume384
Issue number18
Pages (from-to)1719-1730
Number of pages12
ISSN0028-4793
DOIs
Publication statusPublished - 6 May 2021

ID: 65429930